GlassScriptPhysician profile
Paul J Shami
NPI 1992895510
$28,422.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $6,153 · 2022: $2,910.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $5,798.66 | 2019 | |
| Abbvie INC. | $5,327.55 | 2019 | |
| Agios Pharmaceuticals, INC. | $4,200.13 | 2019 | |
| Pfizer INC. | $3,980.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,300.00 | 2020 | |
| Celgene Corporation | $2,062.50 | 2020 | |
| Daiichi Sankyo INC. | $1,935.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $975.00 | 2022 | |
| Gilead Sciences, INC. | $790.00 | 2020 | |
| Aptevo Therapeutics INC | $53.23 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,006.25 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Shami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.